Loading
Continuity Biosciences builds small implanted devices that push chemotherapy straight into a tumour with a mild electric current, aiming for more drug in the cancer and less in the rest of the body; its first trial is in pancreatic cancer.
Continuity Biosciences, LLC launched in November 2024 (release datelined Bradenton, Florida and Houston) to develop drug-delivery platforms licensed from Houston Methodist Hospital, founded by Alessandro Grattoni, Ramakrishna Venugopalan and Robert Whitehead. In oncology its implantable iontophoretic system uses a mild electrical current to deliver chemotherapy directly into tumour tissue, with programmes in pancreatic and oral cavity cancer, and a nanofluidic drug-eluting seed is being developed for breast cancer; other platforms address type 1 diabetes, HIV prevention and medical aesthetics. In June 2025 it acquired Focal Medical to advance targeted drug delivery for pancreatic cancer. A first-in-human phase 1 study tests the implantable iontophoresis device delivering gemcitabine weekly or twice weekly in pancreatic cancer (NCT07481383). Its first registered cancer trial, NCT07481383, was posted on ClinicalTrials.gov in March 2026.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/